Overexpression of DOC-1R Inhibits Cell Cycle G1/S Transition by Repressing CDK2 Expression and Activation
Authors:
- Xing LiuXLXing Liu
- Jinlan GaoJGJinlan Gao
- Xiuyan ShiXSXiuyan Shi
- Xihua HuXHXihua Hu
- Shusen WangSWShusen Wang
- Yang LuoYLYang Luo
Open Access
- 1 January 2013
- journal article
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 9 (6) , 541-549
Abstract
DOC-1R (deleted in oral cancer-1 related) is a novel putative tumor suppressor. This study investigated DOC-1R antitumor activity and the underlying molecular mechanisms. Cell phenotypes were assessed using flow cytometry, BrdU incorporation and CDK2 kinase assays in DOC-1R overexpressing HeLa cells. In addition, RT-PCR and Western blot assays were used to detect underlying molecular changes in these cells. The interaction between DOC-1R and CDK2 proteins was assayed by GST pull-down and immunoprecipitation-Western blot assays. The data showed that DOC-1R overexpression inhibited G1/S phase transition, DNA replication and suppressed CDK2 activity. Molecularly, DOC-1R inhibited CDK2 expression at the mRNA and protein levels, and there were decreased levels of G1-phase cyclins (cyclin D1 and E) and elevated levels of p21, p27, and p53 proteins. Meanwhile, DOC-1R associated with CDK2 and inhibited CDK2 activation by obstructing its association with cyclin E and A. In conclusion, the antitumor effects of DOC-1R may be mediated by negatively regulating G1 phase progression and G1/S transition through inhibiting CDK2 expression and activation.Keywords
This publication has 31 references indexed in Scilit:
- Human Cdc14A regulates Wee1 stability by counteracting CDK-mediated phosphorylationMolecular Biology of the Cell, 2012
- CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cellsGenes & Development, 2012
- Cyclin-dependent kinase inhibitor p21Waf1: Contemporary view on its role in senescence and oncogenesisBiochemistry (Moscow), 2012
- HTLV-I p30 inhibits multiple S phase entry checkpoints, decreases cyclin E-CDK2 interactions and delays cell cycle progressionMolecular Cancer, 2010
- A cancer-derived mutation in the PSTAIRE helix of cyclin-dependent kinase 2 alters the stability of cyclin bindingBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2010
- Cdk2 Is Required for p53-Independent G2/M Checkpoint ControlPLOS Genetics, 2010
- Cdk2 suppresses cellular senescence induced by the c-myc oncogeneNature Cell Biology, 2009
- SIRT2 Suppresses Adipocyte Differentiation by Deacetylating FOXO1 and Enhancing FOXO1's Repressive Interaction with PPARγMolecular Biology of the Cell, 2009
- RETRACTED: Spliceosomal protein E regulates neoplastic cell growth by modulating expression of Cyclin E/CDK2 and G2/M checkpoint proteinsJournal of Cellular and Molecular Medicine, 2008
- Interaction of the CDK2-associated protein-1, p12DOC-1/CDK2AP1, with its homolog, p14DOC-1RBiochemical and Biophysical Research Communications, 2004